Back to search results

New MRI Methods for Heart Failure with Preserved Ejection Fraction (HFpEF)

This study is exploring new ways to use MRI (Magnetic Resonance Imaging) to better understand heart failure with preserved ejection fraction (HFpEF). Researchers are testing new MRI techniques, along with medications like Adenosine or Regadenoson, and O-15 labeled radioactive water for PET imaging. The goal is to improve how we characterize HFpEF and understand microvascular disease in these patients. Success will be measured by how well these new MRI methods can measure blood flow to the heart muscle. You may be able to join if you are over 18, with or without heart disease, or have a diagnosis of HFpEF and can safely undergo an MRI. The current status of this study is unclear.

Study design
This interventional study plans to enroll 100 participants. It is not specified if the study is randomized or blinded.
What's involved
You would undergo MRI scans at rest and during hyperemia (increased blood flow) caused by Adenosine or Regadenoson. You would also have PET imaging with O-15 labeled radioactive water on a different day. The MRI scan itself is expected to take 60-90 minutes.
Compensation
Not stated in the trial record.
Follow-up
Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04600115

New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)

Recruiting
EARLY_PHASE1Ages 18+InterventionalHealth services
University of Utah
~100 participants
Updated 2026-07-07 on ClinicalTrials.gov
What's tested:AdenosineRegadenosonO-15 labeled radioactive waterMRIPET Imaging

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Myocardial perfusion measured with MRI
Measured over Time in the scanner to be 60-90 minutes.

Conditions

MRI Scans

Explore related trials

Healthy VolunteersHeart DisorderHeart failure with normal ejection fraction

NCT04600115

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • university of Utah, Radiology Research

    Salt Lake City, Utahstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Edward DiBella, Ph.D. · PRINCIPAL_INVESTIGATOR · Faculty

Who to contact

Olivia Pratt, BS
[email protected]
801-585-6142
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

All participants will be over the age of 18 and able to provide consent
Group A (volunteers, with or without cardiac disease): Volunteers will be available for at least one study visit
Group B (HFpEF patient volunteers): Volunteers will have a diagnosis of HFpEF and be safe to be imaged with MRI

Exclusion

minors
Critically ill patients, patients on ventilators, patients with unstable angina or with hypotension, asthmatics, and other patients whose medical care or safety may be at risk from undergoing an MRI examination will be excluded.
Patients with claustrophobia will also be excluded from the study if this cannot be controlled with standard methods (valium or benadryl).
Patients with contraindication to MRI (metal implants, or certain types of heart valves),
pregnant patients, , mentally disabled patients and prisoners will be excluded from this study. (All criteria apply to patients and normal volunteers).
Gadolinium nephrotoxicity will be addressed by having patients with abnormal kidney function (GFR\<30) excluded from the study due to the (very small) risk associated with gadolinium contrast agents.
This threshold may be modified, depending on practices determined by the Radiology Department and the IRB.
Patients with a known allergy or contraindication to Adenosine and/or Regadenoson will be excluded from stress MRI cohorts.
All participants that will receive a stress agent will refrain from consuming caffeine for at least 12 hours prior to each MRI
Subjects with a known contraindication to Adenosine and/or Regadenoson will only be enrolled in scans where no stress agent will be administered

What this trial measures

  • Myocardial perfusion measured with MRITime in the scanner to be 60-90 minutes.

    Myocardial perfusion measured with Magnetic Resonance Imaging (MRI) at rest and vasodilation